




RealRate

PHARMACEUTICAL 2022

NGM Biopharmaceuticals INC
Rank 159 of 471

ngmBIO



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of NGM Biopharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NGM Biopharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 51% points. The greatest weakness of NGM Biopharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 20% points.

The company's Economic Capital Ratio, given in the ranking table, is 343%, being 67% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	379,280
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	61,355
Liabilities, Non-Current	5,385
Other Assets	13,036
Other Compr. Net Income	-133
Other Expenses	0
Other Liabilities	0
Other Net Income	360
Other Revenues	77,882
Property and Equipment	10,071
Research and Development	161,712
Selling, General and Administrative Expense	36,865

Output Variable	Value in 1000 USD
Assets	402,387
Liabilities	66,740
Expenses	198,577
Revenues	77,882
Stockholders Equity	335,647
Net Income	-120,335
Comprehensive Net Income	-120,402
BaseVar	373,040
ECR before Limited Liability	261%
Economic Capital Ratio	343%